M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Procedure: leukapheresis

First Posted Date: 2023-01-05

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 117

Registration Number: NCT05672459

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: TTI-101
Drug: Pembrolizumab

First Posted Date: 2022-12-30

Last Posted Date: 2024-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT05668949

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Recruiting

Conditions: Breast Cancer

Interventions: Diagnostic Test: Contrast Enhanced Mammography

First Posted Date: 2022-12-28

Last Posted Date: 2024-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05667532

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
Clear Cell Renal Cell Carcinoma

Interventions: Drug: 177Lu girentuximab
Drug: Nivolumab
Drug: Cabozantinib
Drug: ArabinoFuranosylGuanine [18F]F-AraG

First Posted Date: 2022-12-23

Last Posted Date: 2024-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05663710

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

Not Applicable

Recruiting

Conditions: Breast Cancer
Colorectal Cancer
Ovarian Cancer

Interventions: Behavioral: Genetic Testing and Counseling
Behavioral: Screening Form

First Posted Date: 2022-12-13

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05649072

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Blinatumomab
Drug: Methotrexate
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Prednisone
Drug: Pegfilgrastim
Drug: Inotuzumab ozogamicin
Drug: Rituximab
Drug: Dexamethasone

First Posted Date: 2022-12-09

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT05645718

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Lurbinectedin

First Posted Date: 2022-12-05

Last Posted Date: 2024-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT05636111

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Behavioral: Interview
Behavioral: Questionnaires

First Posted Date: 2022-12-02

Last Posted Date: 2024-08-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05634551

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: MRTX849

First Posted Date: 2022-12-02

Last Posted Date: 2024-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT05634525

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Phase 2

Completed

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Mitotane
Drug: Pembrolizumab

First Posted Date: 2022-12-02

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT05634577

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy